{"accident": 11.03, "ankle fracture": 6.44, "ataxia": 3.54, "balance disorder": 11.17, "bladder disorder": 25.72, "blood test abnormal": 6.16, "constipation": 2.94, "coronavirus infection": 17.34, "cystitis": 16.67, "cystitis noninfective": 18.25, "drug ineffective": 3.1, "dysstasia": 6.72, "epilepsy": 9.98, "facial pain": 5.03, "fall": 6.42, "feeling abnormal": 2.07, "gait disturbance": 16.43, "gait inability": 12.17, "gastrointestinal disorder": 3.64, "general physical health deterioration": 2.89, "generalised tonic-clonic seizure": 7.19, "hip fracture": 7.3, "insomnia": 4.58, "intentional product misuse": 6.72, "intentional underdose": 22.91, "loss of control of legs": 34.94, "loss of therapeutic response": 15.61, "lower limb fracture": 5.46, "lymphocyte count decreased": 6.46, "lymphopenia": 6.72, "mental disorder": 3.99, "mobility decreased": 13.28, "motor dysfunction": 27.66, "multiple sclerosis": 35.42, "multiple sclerosis relapse": 33.18, "muscle spasms": 2.99, "muscle spasticity": 51.5, "muscle tightness": 5.37, "muscular weakness": 3.24, "musculoskeletal disorder": 23.5, "nasopharyngitis": 2.56, "nephrolithiasis": 3.51, "poor quality sleep": 14.21, "prescribed underdose": 14.49, "primary progressive multiple sclerosis": 326.04, "product dose omission in error": 33.88, "product dose omission issue": 6.9, "product residue present": 18.49, "restless legs syndrome": 3.78, "secondary progressive multiple sclerosis": 214.3, "seizure": 3.44, "sensory disturbance": 2.01, "sleep disorder": 3.9, "speech disorder": 2.48, "status epilepticus": 15.08, "stress": 2.16, "temperature intolerance": 10.62, "therapeutic product effect decreased": 8.16, "therapy non-responder": 21.77, "trigeminal neuralgia": 21.29, "underdose": 30.48, "urinary incontinence": 4.97, "urinary tract infection": 8.29, "urinary tract obstruction": 32.94, "vitamin d deficiency": 7.01}